Evidence map›Paper›PMID 23939353›Full record

ArticleCritical care medicine2013

Prognostic and diagnostic value of plasma soluble suppression of tumorigenicity-2 concentrations in acute respiratory distress syndrome.

Ednan K Bajwa, Jessica A Volk, David C Christiani, R Scott Harris, Michael A Matthay, B Taylor Thompson, James L Januzzi, National Heart, Lung and Blood Institute Acute Respiratory Distress Syndrome Network

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Critical care medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Diagnostic and Prognostic Plasma Biomarkers for Idiopathic Pneumonia Syndrome after Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide.Journal of cardiovascular development and disease · 2023
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Observational
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ednan K Bajwa1Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA. 2Department of Medicine, Massachusetts General Hospital, Boston, MA. 3Department of Environmental Health, Harvard School of Public Health, Boston, MA. 4Department of Anesthesia, University of California San Francisco, San Francisco, CA. 5Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Jessica A Volk
David C Christiani
R Scott Harris
Michael A Matthay
B Taylor Thompson
James L Januzzi
National Heart, Lung and Blood Institute Acute Respiratory Distress Syndrome Network
Massachusetts General Hospital · USUniversity of California, San Francisco · US

Funding

MOLECULAR EPIDEMIOLOGY OF ARDSR01HL060710 · NHLBI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI CHRISTIANI, DAVID C · 2000 to 2015
$8.4M
Resolution of Clinical Lung InjuryR37HL051856 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHAY, MICHAEL A. · 2006 to 2015
$3.9M
Early Insulin Therapy and Development of ARDSR01HL086667 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GONG, MICHELLE NG · 2007 to 2011
$2.2M
Surrogate Consent in ResearchR01HL084060 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GONG, MICHELLE NG · 2006 to 2010
$2.1M
Molecular Markers of Risk, Phenotype, and Outcomes in ARDSK23HL087934 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI BAJWA, EDNAN K. · 2008 to 2012
$709k
Molecular Epidemiology of ARDS and Septic ShockK23HL067197 · NHLBI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI GONG, MICHELLE NG · 2001 to 2005
$650k
CCTG NETWORK FOR ARDS TREATMENTN01HR016146 · HR · BAYLOR COLLEGE OF MEDICINE · PI GUNTUPALLI, KALPALATHA K · 2001 to 2001
$297k
NHLBI NIH HHS HL084060NHLBI NIH HHS HL086667NHLBI NIH HHS HL60710NHLBI NIH HHS HL67197NHLBI NIH HHS K23 HL067197NHLBI NIH HHS K23 HL087934NHLBI NIH HHS N01 HR016146NHLBI NIH HHS N01-HR-16146-54NHLBI NIH HHS N01-HR46046-64NHLBI NIH HHS R01 HL060710NHLBI NIH HHS R01 HL084060NHLBI NIH HHS R01 HL086667NHLBI NIH HHS R37 HL051856
6 · The paper itself

Abstract

objectivesSoluble suppression of tumorigenicity-2 is a biomarker of myocardial strain and inflammation. The characteristics of acute respiratory distress syndrome include inflammation and cardiovascular dysfunction. We sought to determine whether plasma soluble suppression of tumorigenicity-2 concentration is associated with outcome and response to conservative fluid management and whether soluble suppression of tumorigenicity-2 concentration discriminates acute respiratory distress syndrome from decompensated heart failure.

designA retrospective analysis of the Fluid and Catheter Treatment Trial, a multi-center randomized controlled trial of conservative fluid management in the acute respiratory distress syndrome, as well as of a cohort of patients with decompensated heart failure.

settingTwenty acute care hospitals. PATIENTS: Eight hundred twenty-six patients with acute respiratory distress syndrome and 209 patients with acutely decompensated heart failure. MEASUREMENTS AND MAIN

resultsNonsurvivors had higher day 0 (p < 0.0001) and day 3 (p < 0.0001) soluble suppression of tumorigenicity-2 concentrations. After adjustment for severity of illness, higher soluble suppression of tumorigenicity-2 concentration was associated with mortality, with odds ratioadj 1.47 (95% CI, 0.99-2.20; p = 0.06) at day 0, 2.94 (95% CI, 2.00-4.33; p < 0.0001) at day 3, and 3.63 (95% CI, 2.38-5.53; p < 0.0001) if soluble suppression of tumorigenicity-2 increased between days. Cumulative fluid balance was more positive among patients with higher day 0 (median, 5,212 mL [interquartile range, 200-12,284 mL] vs median, 2,020 mL [interquartile range, -2,034 to 7,091 mL]; p < 0.0001) and day 3 soluble suppression of tumorigenicity-2 (median, 7,678 mL [interquartile range, 2,217-14,278 mL] vs median, 1,492 mL [interquartile range, -2,384 to 6,239 mL]; p < 0.0001). Soluble suppression of tumorigenicity-2 showed excellent discriminative ability between the Fluid and Catheter Treatment Trial and heart failure populations (area under receiver-operating characteristic curve = 0.98; p < 0.0001).

conclusionsHigher soluble suppression of tumorigenicity-2 concentrations are associated with worse outcome in acute respiratory distress syndrome and may have value for discriminating acute respiratory distress syndrome from heart failure.

Indexed as

AdultAPACHEBiomarkersComorbidityFemaleHemodynamicsHumansMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRespiratory Distress SyndromeRespiratory Function TestsRetrospective StudiesBiomarkers

Identifiers

PMID23939353
PMCPMC3812317
OpenAlexW2076533963

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.